Streetbeat News

Products Services

IMMP

Immutep announces positive clinical data from its INSIGHT-003 trial, evaluating eftilagimod alpha in combination with standard-of-care anti-PD-1 therapy and doublet chemotherapy for 1st line non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:02 pm

SMFL

Smart for Life Inc (NASDAQ:SMFL) has launched a new line of Sports Illustrated protein bars targeting active lifestyles. The bars are non-GMO, cold-pressed, and free of sucralose and preservatives. They will be released in select markets for testing in Q3 2023. The company recently raised $1.58 million via private placement.

Portfolio Pulse from Vandana Singh

May 24, 2023 | 12:02 pm

ELOX

Eloxx Pharmaceuticals plans to advance its drug candidate ELX-02 into a pivotal trial for the treatment of Alport Syndrome with nonsense mutations after achieving remission in a patient during a Phase 2 study.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:02 pm

AAPL

MBGAF

MBGYY

Mercedes-Benz plans to launch digital car key support for Apple's iPhone and Apple Watch, joining other car manufacturers in offering support for Apple's Car Key feature. The feature allows users to unlock and start their cars using their iPhone or Apple Watch.

Portfolio Pulse from Ananya Gairola

May 24, 2023 | 12:00 pm

SMFL

Smart For Life is launching a new line of Sports Illustrated protein bars, which will be available at sportsillustratednutrition.com and the company plans to launch them in retail stores and additional online channels in the coming weeks.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:00 pm

PHIO

Phio Pharmaceuticals has initiated a collaborative clinical trial with AgonOx's tumor infiltrating lymphocyte (TIL) and Providence Cancer Institute using PH-762, a potential cancer treatment. The trial aims to evaluate the safety and efficacy of the combination therapy.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:37 am

PHIO

Phio Pharmaceuticals has initiated a collaborative clinical trial with its PH-762 compound, AgonOx's tumor infiltrating lymphocyte program (AGX148), and Providence Cancer Institute. The trial aims to evaluate the safety and efficacy of the combined therapy in cancer patients.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:36 am

CYBN

Cybin Inc. has initiated the first-in-human dosing of CYB004 in a Phase 1 clinical trial, evaluating intravenous N,N-dimethyltryptamine (IV DMT) and CYB004 in healthy volunteers. Robust psychedelic effects were observed within two minutes, with no safety concerns reported.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:33 am

LILM

Lilium N.V. (NASDAQ:LILM) has signed an agreement with ASL Group for the delivery of six all-electric vertical take-off and landing Pioneer Edition Jets. The agreement converts a previous Memorandum of Understanding between the two companies.

Portfolio Pulse from Charles Gross

May 24, 2023 | 11:18 am

EVGN

Lavie Bio has secured Canadian regulatory approval for Thrivus, a bio-inoculant seed treatment that increases Hard Red Spring Wheat production by improving soil nutrient availability and efficiency, mitigating environmental stresses, and enhancing production in sub-optimal areas.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:16 am